According to Lexicon Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $1.2 M. In 2022 the company made a revenue of $0.13 M a decrease over the years 2021 revenue that were of $0.29 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $1.2 M | 766.91% |
2022 | $0.13 M | -53.36% |
2021 | $0.29 M | -98.76% |
2020 | $23.99 M | -92.55% |
2019 | $0.32 B | 406.95% |
2018 | $63.53 M | -29.67% |
2017 | $90.33 M | 8.4% |
2016 | $83.33 M | -35.9% |
2015 | $0.13 B | 468.89% |
2014 | $22.85 M | 928.53% |
2013 | $2.22 M | 104.04% |
2012 | $1.08 M | -41.1% |
2011 | $1.84 M | -62.33% |
2010 | $4.9 M | -54.13% |
2009 | $10.7 M | -66.89% |
2008 | $32.32 M | -35.51% |
2007 | $50.11 M | -31.15% |
2006 | $72.79 M | -3.81% |
2005 | $75.68 M | 22.58% |
2004 | $61.74 M | 44.12% |
2003 | $42.83 M | 21.7% |
2002 | $35.2 M | -88.48% |
2001 | $0.30 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Thermo Fisher Scientific TMO | $42.85 B | 3,556,497.51% | ๐บ๐ธ USA |
Illumina ILMN | $4.50 B | 373,675.93% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | $13.11 B | 1,088,464.32% | ๐บ๐ธ USA |
Ultragenyx RARE | $0.43 B | 35,937.26% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | $0.13 B | 10,797.43% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | $0.11 B | 9,554.27% | ๐บ๐ธ USA |
Aerie Pharmaceuticals AERI | $0.21 B | 17,654.44% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 200,665.64% | ๐บ๐ธ USA |
Eterna Therapeutics ERNA | $0.06 M | -94.36% | ๐บ๐ธ USA |